Virtus ETF Advisers LLC Precision Biosciences Inc Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.15 - $3.34 $21,807 - $63,336	-18,963 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $3,306 - $8,667	-1,117 Reduced 5.56%	18,963 $58,000
Q4 2021 Feb 14, 2022	BUY	$7.4 - $11.66 $13,112 - $20,661	1,772 Added 9.68%	20,080 $149,000
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $8,803 - $13,569	-959 Reduced 4.98%	18,308 $211,000
Q2 2021 Aug 10, 2021	SELL	$8.07 - $12.52 $146,260 - $226,912	-18,124 Reduced 48.47%	19,267 $241,000
Q1 2021 May 17, 2021	BUY	$8.57 - $15.79 $5,587 - $10,295	652 Added 1.77%	37,391 $387,000
Q4 2020 Feb 12, 2021	SELL	$5.98 - $12.47 $26,664 - $55,603	-4,459 Reduced 10.82%	36,739 $306,000
Q3 2020 Nov 13, 2020	SELL	$4.65 - $8.73 $26,216 - $49,219	-5,638 Reduced 12.04%	41,198 $254,000
Q2 2020 Aug 05, 2020	BUY	$4.66 - $8.7 $55,416 - $103,460	11,892 Added 34.03%	46,836 $390,000
Q1 2020 May 14, 2020	SELL	$5.05 - $15.01 $25,749 - $76,535	-5,099 Reduced 12.73%	34,944 $211,000
Q4 2019 Feb 13, 2020	BUY	$6.32 - $19.66 $253,071 - $787,245	40,043 New	40,043 $556,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $537M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.